Broad Institute

JANUARY 30, 2024

In others, an infection can cause the immune system to spin out of control, leading to sepsis — organ dysfunction that lacks effective treatments and is often fatal. For his medical residency, he moved to Massachusetts General Hospital, where he was enthralled with seeing patients, especially the ones with perplexing infections.

Hospitals 137

Hospitals Virus Medical Schools Science 137

The Pharma Data

FEBRUARY 1, 2021

HOUSTON, TX, February 01, 2021 /24-7PressRelease/ — It has been just over a year since the COVID-19 virus arrived in the United States, already claiming the lives of over 400,000 Americans. Medical professionals are desperately seeking effective treatments as hospitals are continuously overwhelmed with COVID-19 patients.

Treatment 52

Treatment Virus Hospitals Pharmaceutical Companies 52

The Pharma Data

DECEMBER 9, 2020

9, 2020 — In a sign that the COVID-19 pandemic is entering its most dire stage yet, new federal data show that more than a third of Americans now live in areas where hospitals are critically short of intensive care beds. WEDNESDAY, Dec. When you don’t have that capacity, that means people will die.”

Hospitals 52

Hospitals Doctors Virus Government 52

Broad Institute

FEBRUARY 8, 2024

By Allessandra DiCorato February 8, 2024 Credit: NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland Scanning electron image of the Lassa virus budding off a cell. Other scientists had discovered that this gene was critical for the Lassa virus to enter cells.

Research 81

Research Virus Hospitals Disease 81

The Pharma Data

SEPTEMBER 10, 2020

The disruption to hospitals in England during the pandemic has meant the number of patients facing long waits for routine operations has soared. But there are some encouraging signs, with treatments happening in hospitals on the increase. Image copyright. Getty Images. The numbers coming to Accident and Emergency topped 1.7m

Hospitals 52

Hospitals Treatment Virus 52

The Pharma Data

APRIL 8, 2022

Using a Human Lung Chip that replicates the structures and functions of the lung air sac, or “alveolus,” the research team discovered that applying mechanical forces that mimic breathing motions suppresses influenza virus replication by activating protective innate immune responses. During his Ph.D.

Virus 52

Virus Immune Response Disease Clinical Trials 52

The Pharma Data

JANUARY 26, 2021

While the preliminary nature of Phase 2 results from COVID-19 neutralizing monoclonal antibodies may have limited acceptance of treatment, these Phase 3 data further strengthen the available evidence,” said Daniel Skovronsky, M.D., INDIANAPOLIS, Jan. Lilly’s chief scientific officer and president of Lilly Research Laboratories.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

NOVEMBER 18, 2020

18, 2020 /PRNewswire/ — Tampa General Hospital provided the first monoclonal antibody treatment to a COVID-19 positive patient today. This single dose infusion-based treatment is provided on an outpatient basis and marks a dramatic shift in COVID-19 care. Currently receiving immunosuppressive treatment.

Hospitals 40

Hospitals Treatment Virus Science 40

Codon

AUGUST 27, 2024

Consider Alice, a 49-year-old woman (and hypothetical patient) who walked into a hospital in Puerto Rico with joint pain, a headache, nausea, and a low fever. While Alice was lucky that her infections were identified at the hospital, it would have been even better had they been identified before she arrived.

DNA 100

DNA Laboratories Hospitals Virus 100

The Pharma Data

SEPTEMBER 30, 2020

While recognising the huge burden placed on the NHS, their report said cancelled treatments and surgery had left some “in limbo” and others “too scared” to seek medical help. Communicate with patients better about any delays to their treatment. “I am a single mum with teenagers at home.

Virus 52

Virus Government Nurses Hospitals 52

The Pharma Data

NOVEMBER 10, 2020

Antibody Treatment Approved for Emergency Use Against Early COVID-19. 10, 2020 — Eli Lilly’s experimental antibody treatment for COVID-19 was given emergency approval by the U.S. ” The agency warned that it should not be used in patients who are already hospitalized with the illness. Professional. government.

Treatment 52

Treatment Government Hospitals FDA 52

The Pharma Data

JANUARY 17, 2021

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination. BARCELONA, Spain , Jan. 18, 2021 /PRNewswire/ — Grifols (MCE: GRF, MCE: GRF.P,

Clinical Trials 52

Clinical Trials Treatment Trials Virus 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 129

Therapies Virus DNA Clinical Trials 129

The Pharma Data

APRIL 16, 2021

for the treatment of COVID-19 – as planned with the FDA – follows the modification of contracts with the U.S. 1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. This request is not due to any new safety concern. All sites in the U.S.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

OCTOBER 22, 2020

FDA Approves Veklury (remdesivir) for the Treatment of COVID-19. Food and Drug Administration (FDA) has approved the antiviral drug Veklury (remdesivir) for the treatment of patients with COVID-19 requiring hospitalization. As an antiviral drug, Veklury works to stop replication of SARS-CoV-2, the virus that causes COVID-19.

FDA Approval 52

FDA Approval Treatment FDA Hospitals 52

The Pharma Data

MARCH 23, 2022

“When the COVID-19 pandemic started, our multidisciplinary research teams switched our investigations of other viruses and bacteria to focus on a potential treatment for what was then a challenging new virus for us,” says Children’s Center microbiologist Lori Jones-Brando, Ph.D., alone each year.

Virus 52

Virus Immune Response Research Treatment 52

The Pharma Data

MARCH 22, 2022

NYSE: PFE) announced today an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), to 95 low- and middle-income countries, pending authorization or approval. Pfizer Inc.

Treatment 52

Treatment Virus Therapies Hospitals 52

The Pharma Data

DECEMBER 29, 2020

29, 2020 /PRNewswire/ — Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. TARRYTOWN, N.Y. , Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Trials Clinical Trials Production 52

The Pharma Data

SEPTEMBER 1, 2020

The Phase 3 trial did not meet the primary or secondary endpoints compared with placebo and established hospital care. Overall, it did not help those with less severe cases of the virus and in some cases the trial environment led to COVID-19 pneumonia infections and even death in a few instances.

Trials 52

Trials Treatment Clinical Trials Vaccine 52

The Pharma Data

DECEMBER 17, 2020

(NASDAQ: REGN ) today announced that the New England Journal of Medicine (NEJM) has published initial clinical data from an ongoing seamless Phase 1/2/3 trial of the antibody cocktail casirivimab and imdevimab in non-hospitalized patients with COVID-19. “The investigational cocktail is now available to indicated high-risk U.S.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

The Pharma Data

NOVEMBER 16, 2020

16, 2020 (American Heart Association News) — The rate of resuscitation for cardiac arrests outside of a hospital setting decreased during the first weeks of the COVID-19 pandemic, new research shows. The researchers looked at 52,183 out-of-hospital cardiac arrest cases in the U.S. MONDAY, Nov. “That was unexpected.

Hospitals 52

Hospitals Science Virus Research 52

The Pharma Data

APRIL 27, 2023

There are no RSV vaccines or specific treatments currently available for older adults. RSV causes over 270,000 hospitalisations and approximately 20,000 in-hospital deaths in adults aged 60 years and older each year in Europe.

Virus 40

Virus Vaccine Trials Clinical Trials 40

The Pharma Data

JANUARY 13, 2021

patients hospitalized with COVID-19. We are pleased vaccines are now approved for the prevention of COVID-19; however, a significant unmet need remains for effective treatments for symptomatic patients. Patient Population: 45 hospitalized patients with COVID-19. LONDON and RALEIGH, N.C., David Zaccardelli, Pharm.

Hospitals 52

Hospitals Clinical Trials Therapies Treatment 52

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

APRIL 25, 2021

Nirsevimab demonstrate d protect ion against respiratory syncytial virus disease in healthy infants in Phase 3 trial. Respiratory Syncytial Virus (RSV) is the leading cause of hospitalization in all infants. RSV is the most common cause of LRTI and the leading cause of hospitalizations in all infants. 1 – 5.

Virus 40

Virus Trials Disease Hospitals 40

The Pharma Data

MARCH 3, 2022

If approved by the FDA, this maternal immunization has the potential to be the first vaccine candidate to help protect infants in their vulnerable first months of life from disease caused by this highly-contagious virus. Burden of RSV RSV is a contagious virus and a common cause of respiratory illness. Pfizer Inc.

Virus 52

Virus Vaccine Clinical Trials Trials 52

The Pharma Data

NOVEMBER 9, 2020

Bamlanivimab is authorized for the treatment of mild to moderate COVID-19 in adults and pediatric patients 12 years and older with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization. It is not known if bamlanivimab is safe and effective for the treatment of COVID-19. .

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52

The Pharma Data

JULY 23, 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Ronapreve (casirivimab and imdevimab), for the treatment of patients with mild to moderate COVID-19 via intravenous infusion. Roche’s Chief Medical Officer and Head of Global Product Development.

Treatment 52

Treatment Virus Clinical Trials Pharmaceuticals 52

PLOS: DNA Science

JULY 27, 2023

The owners of the felines all reported feeding their pets raw meat, and samples of the meat revealed not only flu virus genetic material, but also infectious virus. The fear is that a variant of the deadly virus might emerge that infects people, and, worst-case-scenario, passes from person to person. emerged in late 2021.

Disease 95

Disease DNA Virus RNA 95

Broad Institute

DECEMBER 6, 2023

For many immune-mediated diseases, there's no cure or treatment. Some patients develop resistance to treatment and we cannot predict who they will be. By Allessandra DiCorato December 6, 2023 Credit: Len Rubenstein (right photo) Ang Cui (left) and Nir Hacohen (right). What makes this study significant?

Immune Response 138

Immune Response RNA Disease Medical Schools 138

The Pharma Data

OCTOBER 30, 2020

NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. About the REGN-COV2 Trial in Hospitalized Patients. Regeneron Pharmaceuticals, Inc.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

DECEMBER 20, 2020

20 , 2020 /PRNewswire/ — The broad spectrum antiviral therapeutic, ‘hzVSF-v13(humanized Virus Suppressing Factor)’ being developed by ImmuneMed , is on track to progress as a treatment for the COVID-19 pneumonia patients. CHUNCHEON, South Korea , Dec. Media Contact.

Clinical Trials 40

Clinical Trials Treatment Trials Hospitals 40

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. In order to do so, the DSMC may review unblinded study information (on a patient level or treatment group level) during the conduct of the trial.

Hospitals 52

Hospitals Trials International Clinical Trials 52

The Pharma Data

MARCH 23, 2021

(NYSE: PFE) announced today that it is progressing to multiple ascending doses after completing the dosing of single ascending doses in a Phase 1 study in healthy adults to evaluate the safety and tolerability of an investigational, novel oral antiviral therapeutic for SARS-CoV-2, the virus that causes COVID-19.

Virus 52

Virus Vaccine Hospitals Pharmacokinetics 52

The Pharma Data

NOVEMBER 21, 2020

In a clinical trial of patients with COVID-19, casirivimab and imdevimab, administered together, were shown to reduce COVID-19-related hospitalization or emergency room visits in patients at high risk for disease progression within 28 days after treatment when compared to placebo. SILVER SPRING, Md. , Hahn , M.D.

FDA 40

FDA Treatment Hospitals Clinical Trials 40

DrugBank

JUNE 13, 2024

These innovative technologies are changing how medications reach their targets within the body, leading to more effective treatments with fewer side effects.   Take cancer treatment, for example. Implantable insulin pumps equipped with continuous glucose monitoring (CGM) sensors can update old diabetes treatment options.

Therapies 98

Therapies Drugs DNA Treatment 98

Codon

JANUARY 21, 2024

yellow fever, malaria, and dengue), evaluating new drugs or treatments, and studying pathogenesis, the process by which a disease develops. Scientists studied black men infected with syphilis for several decades while withholding known treatments. How are disease targets selected for challenge trials?

Vaccine 124

Vaccine Trials Disease Treatment 124